DABRA Laser to be Presented as a Frontline Therapy for CLI at the 2019 SCAI Scientific Sessions

“The unique DABRA catheter and laser system is a highly effective frontline therapy for peripheral artery disease (PAD) that provides my patients excellent results, shorter rehabilitation time, and shorter hospitalizations,” said Dr. Ansari, Director of the Cardiac Cath Lab, Structural Heart & Interventional Cardiology Research and Assistant Professor, Division of Cardiology, at Texas Tech University Health Sciences Center. “As demonstrated in this case, DABRA is a new, effective technology for the revascularization of CLI and acute limb ischemia where other devices could not rescue the limb.”

The presentation, titled, “Innovation Update: Redefining Excimer Laser Photoablation – A Case Review Demonstrating the Utility and Versatility of DABRA as a Front Line Therapy for CLI,” will take place on Tuesday, May 21 at 3:50 pm in the Innovation Showcase Theater. For more information about Dr. Ansari’s presentation at SCAI, please visit Ra Medical Systems at Booth No. 408.

“Recent analysis suggests that 17.6 million people in the U.S. suffer from PAD,” said Dean Irwin, CEO, Ra Medical Systems. “We at Ra Medical are dedicated to providing a better solution for these patients.”

DABRA (Destruction of Arteriosclerotic Blockages by laser Radiation Ablation) is a novel, minimally invasive excimer laser system that non-thermally and photochemically ablates channels in vascular blockages. The technology reduces all plaque types into their fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by dissolving them without generating potentially harmful particulates. Unlike many mechanical, acoustic or thermal treatments for PAD that may damage the arterial wall, DABRA treats blockages with minimal vascular trauma.

SCAI (Society for Cardiovascular Angiography and Interventions) is taking place in Las Vegas, NV, at The Cosmopolitan’s Innovation Showcase Theater through May 22, 2019. Each year, the SCAI annual meeting attracts 2,000 physicians, cardiovascular professionals, hospital administrators, academics and industry professionals from around the world to share knowledge, clinical expertise and the latest medical advances, with the single goal of advancing care to save and enhance lives.

About Ra Medical Systems

Ra Medical Systems is a commercial medical device company developing and marketing innovative excimer laser systems for the treatment of vascular and dermatologic diseases. DABRA launched in 2017 for the endovascular treatment of blockages resulting from lower extremity vascular disease. Pharos launched in 2004 for the treatment of dermatological disorders including psoriasis, vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra Medical’s core excimer laser technology platform that produces 308 nanometer light, a UVB wavelength that studies have demonstrated increases T-cell apoptosis, or cell death, which may produce a beneficial, targeted immunosuppressive effect. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, California. The vertically integrated facility is ISO 13485 certified and is licensed by the state of California to manufacture sterile, single-use catheters in controlled environments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Ra Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Ra Medical’s future expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential benefits to patients and physicians using the DABRA catheter and laser system. Ra Medical’s expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of DABRA and Pharos and procedures performed using such devices by physicians, payors, and other third parties; development and acceptance of new products or product enhancements; clinical and statistical verification of the benefits achieved via the use of Ra Medical’s products; the Company’s ability to effectually manage inventory; Ra Medical’s ability to recruit and retain management and key personnel; Ra Medical’s need to comply with complex and evolving laws and regulations; intense and increasing competition and consolidation in Ra Medical’s industry; the impact of rapid technological change; costs and adverse results in any ongoing or future legal proceedings; adverse outcome of regulatory inspections; and the other risks and uncertainties described in Ra Medical’s news releases and filings with the Securities and Exchange Commission. Information on these and additional risks, uncertainties, and other information affecting Ra Medical’s business and operating results is contained in Ra Medical’s quarterly report on Form 10-Q for the quarter ended March 31, 2019 and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Ra Medical investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (www.ramed.com), our investor relations website (https://ir.ramed.com/), press releases, SEC filings, and public conference calls in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.